HardwareGothenburg, SwedenFounded 2016· One of 1805 Hardware companies tracked by AMPulse
Develops innovative 3D bioprinting systems including state-of-the-art bioprinters and bioinks used for printing human tissues and organs.
CEO / Founder
Kevin Coakley
Stage
Public
Total Funding
Publicly Traded
Latest Round
IPO
Key Investors
Erik Penser Bank AB, Other institutional and strategic investors
Technology & Products
Key Products
Universal bioink, tissue-specific bioinks, 3D bioprinting systems.
Technological Advantage
Scalable automation solutions and integrated workflows that lower cost barriers and streamline bioprinting processes.
Differentiation
Value Proposition
Enables creation of complex, biomimetic tissues for drug discovery, personalized medicine, regenerative therapies, and cosmetic testing at lower costs with scalable, user-friendly technologies.
How They Differentiate
Combines scalable, cost-effective bioprinting hardware with an extensive portfolio of bioinks and a strong focus on automation and integrated workflows.
Market & Competition
Target Customers
Researchers, pharmaceutical companies, healthcare providers, and academic institutions
Achieved rapid market valuation at IPO and significant revenue growth through strategic acquisitions and global expansion
Major Milestones
["Released the world’s first universal bioink","IPO in 2017","Acquisition of Dispendix GmbH in 2018","Strategic acquisitions including Advanced BioMatrix","Key partnerships with industry leaders such as MedImmune"]
Notable Customers
Harvard University, Merck, Novartis, AstraZeneca, Johnson & Johnson, U.S. Army, Toyota, MIT, Takara Bio
CELLINK positions itself as a premier bioprinting company, combining scalable hardware with an extensive bioink portfolio to lower cost barriers in tissue engineering. Its proprietary bioink formulations and clean chamber technology aim to mimic natural cell growth environments, differentiating it from generalist 3D printing firms.
The company's core offering includes 3D bioprinting systems and a range of bioinks, from universal to tissue-specific formulations. These tools enable the fabrication of complex, biomimetic tissues for applications in drug discovery, personalized medicine, regenerative therapies, and cosmetic testing.
Customers include pharmaceutical companies such as Merck, Novartis, AstraZeneca, and Johnson & Johnson, as well as academic institutions like Harvard University and MIT. The U.S. Army and Toyota are also named users, indicating defense and industrial research interest. Products are reportedly used by more than 15 of the top 25 diagnostics companies.
CELLINK went public in 2017 and raised $315 million in total funding, with investors including Erik Penser Bank AB. Strategic acquisitions such as Dispendix GmbH and Advanced BioMatrix expanded its automation and biomaterials capabilities. Partnerships with Chalmers University of Technology and MedImmune support continued R&D. The company competes with Organovo and Allevi, but its integrated hardware-bioink workflow and automation focus provide a defensible position in the precision dispensing market.